Back to Main Menu

Products & Services

Red Blood Cell-Based Liquid Biopsy

One of the major advances in the field of precision cancer treatment is the advent of non-invasive liquid biopsy. Most existing technologies involve the detection of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood plasma. However, a major bottleneck with this approach is that these biomarkers are shed from tumors only at a later stage of the disease. This means that we will miss the chance to detect the disease at its earliest stages, when the chance of effective treatment is the highest.

At MBM, we have developed a Red Blood Cell-based platform, a new approach to liquid biopsy that addresses the inherent problems associated with methods based on ctDNA and CTCs. We are currently performing clinical validation studies on the AccuRed platform in stage I non-small cell lung cancer patients.

Our technology platforms are available for both clinical usage and research collaboration. Click here to learn how we can work together.

Latest Blog Posts

News and healthcare tips

en_USEnglish